Abstract: The present invention relates to a multilayered wound dressing particularly for wound treatment in the granulation and epithelization phase. The wound dressing comprises a) a first layer as a wound contact layer having a first side and a second side, and b) at least one second layer as an absorbent layer having a first side and a second side and comprising a hydrophilic polyurethane foam, wherein the polyurethane foam comprises a water fraction of at least 10% by weight of water.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

Abstract: A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided.

Abstract: The present invention provides an oral film-form base which has a rapid dissolution profile in the mouth and sufficient film strength, and gives an improved taking property by foaming in the mouth. The oral film-form base includes an edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher, a foaming agent, and an auxiliary foaming agent, wherein the foaming agent is foamable in the presence of water, and the foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 ?m, and are included in particle states.

Abstract: The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition.

Abstract: A method of freshening the air or a surface is provided. The method comprises the steps of: providing a freshening composition, the freshening composition comprising a plurality of particles and a structurant system; and spraying the freshening composition in the form of a plurality of spray droplets, wherein the plurality of spray droplets have: a normalized D(90) value of less than 2.5, when sprayed from a TS800 sprayer according to the SPRAY D(90) NORMALIZED AND SPRAY D(4,3) NORMALIZED TEST METHOD described herein, a residue value of less than about 8 at 5 sprays, according to the RESIDUE TEST METHOD described herein, and a phase stability grade of 1 or 2, according to the PHASE STABILITY GRADE AT 25° C. TEST METHOD described herein.

Abstract: A freshening composition is provided. The freshening composition includes a plurality of particles, a structurant system, and an aqueous carrier. The composition has a spray shear viscosity, as measured according to the SPRAY SHEAR VISCOSITY TEST METHOD described herein, of less than about 0.025 Pa-s. The composition has a creep recovery ratio of at least about 0.1, as measured according to the CREEP RECOVERY RATIO TEST METHOD described herein, or a yield stress of greater than 0 Pa and less than 1.0 Pa, as measured by the YIELD STRESS TEST METHOD described herein.

Abstract: The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

Abstract: The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule and a fill formulation comprising one or more antiprogestins dispersed in a mixture of isopropyl palmitate or isopropyl myristate and a polyethylene glycol.

Abstract: The present disclosure relates generally to compositions and methods for production of three-dimensional constructs with high mechanical strength and/or stiffness.

Abstract: The invention is a solid oral dosage form that is designed to deliver a supraphysiological dose of molecular iodine of 3 to 60 mg per day. The solid oral dosage form is designed to have a low risk of thyroid related adverse clinical events for patients with deficiencies of certain minerals. The solid oral dosage form includes a source of iodine, a reactive agent, and calcium or iron. The solid oral dosage form may include one or more of selenium, vitamin A, vitamin D, zinc, gamma-linolenic acid, vitamin B1, and magnesium. The solid dosage form may further comprise an enteric coating that coats ingredients that are absorbed predominantly from the intestines, such as vitamin A and D, and does not coat the source of iodine and the reactive agent.

Abstract: A pharmaceutical composition in form of an aqueous colloid or an aqueous suspension of particles up to a size of 100 ?m comprises or consists of amphiphilic sulfonate or sulfate of a hydrophilic cancer drug having a solubility in water or aqueous body fluid of less than 0.1% by weight. Also disclosed are the particles in powderous form, methods for their production and for the production of the colloid and the courser suspension, a method of treating liver cancer, in particular solid liver cancer tumours, by administration of the pharmaceutical composition, and a method of designing a composition according to the invention.

Abstract: The present invention provides a composition for preventing, improving or treating periodontal diseases comprising extract of mangosteen. The composition of the present invention has excellent anti-bacterial and anti-inflammatory effects against bacteria inducing periodontal diseases as comprising extract of mangosteen, or alpha-mangosteen or gamma-mangosteen derived from thereof, and thereby it can be widely used for medicines and foods for preventing, improving or treating periodontal diseases.

Abstract: Provided are a composition for hot-melt extrusion which can be hot-melt extruded at a temperature lower than a conventional temperature and therefore free of heat-induced deactivation of a drug; and a method for producing a hot-melt extrusion product which is simpler than a spray-drying method. More specifically, provided is a composition for hot-melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more. Also provided is a method for producing a hot-melt extrusion product including a step of hot-melt extruding a composition for hot-melt extrusion including a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more at a hot-melt temperature of melting temperature of the hypromellose acetate succinate or higher, or at a hot-melt temperature equal to or higher than a temperature at which both the hypromellose acetate succinate and the drug become melted.

Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.

Abstract: A kit of parts for use in prevention and/or treatment of a non-oral treatment site, such as, sores, wounds, ulcers or the like, or a fistula or otitis. The kit of parts comprises a first aqueous component comprising one or more amino acids, and a second aqueous component comprising an active halogen compound, wherein the pH of the first component and/or the second component is about 9 to 11.5. There is also provided a treatment preparation prepared from the components and uses thereof in the prevention and/or treatment of a non-oral treatment site, such as, sores, wounds, ulcers or the like, or a fistula or otitis.

Abstract: A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects.

Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.